KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms
Neurocrine Biosciences, Inc. announced new long-term data from the KINECT 4 Phase III open-label study demonstrate that once-daily INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), improved TD symptoms through 48 weeks of open-label treatment and was generally well tolerated. TD is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. These data were presented at the ACNP Annual Meeting. In addition to the KINECT 4 Phase III study results, Neurocrine also presented pooled data...
